

Kent Academic Repository

Full text document (pdf)

Citation for published version

Victor, Andrea R. and Tyndall, Jack C. and Brake, Alan J. and Lepkowsky, Laura T. and Murphy, Alex E. and Griffin, Darren K. and McCoy, Rajiv C. and Barnes, Frank L. and Zouves, Christo G. and Viotti, Manuel (2019) One hundred mosaic embryos transferred prospectively in a single clinic: exploring when and why they result in healthy pregnancies. *Fertility and Sterility*, 111

DOI

<https://doi.org/10.1016/j.fertnstert.2018.10.019>

Link to record in KAR

<https://kar.kent.ac.uk/72238/>

Document Version

Author's Accepted Manuscript

Copyright & reuse

Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

Versions of research

The version in the Kent Academic Repository may differ from the final published version.

Users are advised to check <http://kar.kent.ac.uk> for the status of the paper. **Users should always cite the published version of record.**

Enquiries

For any further enquiries regarding the licence status of this document, please contact:

researchsupport@kent.ac.uk

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at <http://kar.kent.ac.uk/contact.html>

1
2
3
4 **One Hundred Mosaic Embryos Transferred Prospectively In A Single Clinic:**
5
6 **Exploring When And Why They Result In Healthy Pregnancies**
7
8
9

10
11 Running Title: Mosaic embryos and healthy pregnancies
12
13
14

15
16 Authors:
17

18 Andrea R. Victor, M.S.^{1,2}, Jack C. Tyndall, B.A.¹, Alan J. Brake, M.S.¹, Laura T.
19 Lepkowsky, B.S.¹, Alex E. Murphy, B.S.¹, Darren K. Griffin, Ph.D., DSc², Rajiv C.
20 McCoy, Ph.D.³, Frank L. Barnes, Ph.D.^{1,4}, Christo G. Zouves, M.D.^{1,4}, and Manuel
21 Viotti, Ph.D.^{1,4,*}
22
23
24
25
26
27
28
29

30
31 ¹ Zouves Fertility Center, Foster City, California, USA;
32

33 ² School of Biosciences, University of Kent, Canterbury, United Kingdom;
34

35 ³ Department of Biology, Johns Hopkins University, Baltimore, Maryland, USA.
36

37 ⁴ Zouves Foundation for Reproductive Medicine, Foster City, California, USA.
38
39

40
41 *Corresponding author information:
42

43 E-mail: manuel@zouvesfoundation.org
44

45 Telephone: ++1 646 784 1008
46

47 Address: Zouves Foundation For Reproductive Medicine, 1241 E Hillsdale Blvd,
48

49 Suite 100, Foster City, CA 94131, USA
50
51

52
53 The authors of this study have nothing to disclose.
54
55
56
57
58
59
60
61
62
63
64
65

Capsule: Chromosomal mosaicism in embryos can exist in a variety of forms, and different characteristics determine the clinical outcome of mosaic embryo transfers.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ABSTRACT

Objective: To investigate the parameters of mosaicism and biological mechanisms leading to healthy pregnancies from mosaic embryo transfers.

Design: Prospective study.

Setting: IVF center and associated research laboratory.

Patient(s): 59 patients.

Interventions: Embryos underwent blastocyst-stage preimplantation genetic testing for aneuploidy (PGT-A) by next-generation sequencing (NGS). Trophectoderm (TE) biopsies containing 20-80% abnormal cells were deemed mosaic, and corresponding blastocysts were transferred. Mosaic embryos donated to research were examined for karyotype concordance in multiple biopsies, and assessed for cell proliferation and death by immunofluorescence and computational quantitation.

Main Outcome Measure(s): Chemical start of pregnancy, implantation, fetal heartbeat, birth.

Results: Globally, mosaic embryos showed inferior clinical outcomes than euploid embryos. Aneuploid cell percentage in TE biopsies did not correlate with outcomes, but type of mosaicism did, as embryos with single mosaic segmental aneuploidies fared better than all other types. Mosaic blastocysts generated from oocytes retrieved at young maternal ages (≤ 34 years) showed better outcomes than those retrieved at older maternal ages. Mosaic embryos displayed low rates of karyotype concordance between multiple biopsies, and showed significant elevation of cell proliferation and death compared to euploid embryos.

1
2
3
4 **Conclusions:** After euploid embryos, mosaic embryos can be considered for transfer
5
6 prioritizing those of the single segmental mosaic type. If a patient has mosaic
7
8 embryos available that were generated at different ages, preference should be given
9
10 to those made at younger ages. Intra-blastocyst karyotype discordance and
11
12 differential cell proliferation and death might be reasons by which embryos classified
13
14 as mosaic can result in healthy pregnancies and babies.
15
16
17
18
19
20

21 **Keywords:** Mosaic; PGT-A; Blastocyst; Aneuploidy; Next-generation sequencing
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

INTRODUCTION

Chromosomal mosaicism, or the presence of two or more chromosomally distinct cell lines within an individual, has clinical implications both in naturally conceived and IVF pregnancies. Among natural pregnancies it is known to affect ~2% of all gestations in the form of confined placental mosaicism (CPM). This condition entails discordance of karyotypes between fetal and placental cells and can lead to adverse obstetric outcomes including intrauterine growth retardation or placental insufficiency (1, 2). Among IVF embryos, data from a flurry of recent studies suggests that, in general, mosaicism results in decreased pregnancy rates compared to normal embryos (3-7). However, numerous forms of mosaicism exist, and refinement of these interpretations is needed. The contemporary IVF clinic must grapple with the question: What should be done with mosaic embryos, should they be transferred, and if so, how should they be prioritized?

Preimplantation genetic testing for aneuploidy (PGT-A) at the blastocyst stage is currently used in over 20% of all IVF treatments in the USA, and growing (3). It entails analysis of the chromosomal content of a representative 5-10 cell biopsy taken from the trophectoderm (TE) tissue and produces a readout estimating the copy number of each chromosome. For autosomes, a copy number two is indicative of a disomy (considered normal/euploid), while copy numbers of one and three are indicative monosomy and trisomy, respectively (considered abnormal/aneuploid). In such cases, the clinical decision to de-select aneuploid embryos for transfer is straightforward. A third classification category exists, namely samples with analysis

1
2
3
4 readouts producing values at intermediate levels between whole numbers. Such
5
6 profiles are consistent with mosaicism, which would indicate the presence of both
7
8 euploid and aneuploid cells in the source blastocyst. While previous technologies for
9
10 PGT-A were limited in identifying this condition, next-generation sequencing (NGS) is
11
12 now widely recognized as the most accurate platform for revealing and quantifying
13
14 mosaicism (8).
15
16
17

18
19 In order to better define the characteristics and genetic abnormalities affecting
20
21 the clinical outcomes of mosaic embryos, we performed an analysis of the
22
23 prospective transfer of 100 embryos classified as mosaic via NGS-based PGT-A in a
24
25 single IVF center. Furthermore, we explore biological mechanisms that can lead a
26
27 mosaic blastocyst to ultimately result in a healthy baby.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

MATERIALS AND METHODS

Patients and Embryos

Embryos derived from patients seeking infertility treatment at a private IVF center were generated by intracytoplasmic sperm injection (ICSI) and cultured to the blastocyst stage as previously described (9). Blastocysts were assessed with the Gardner evaluation system (10) and subjected to a 5-10 cell TE biopsy and vitrified until further use. Biopsies were processed for PGT-A (see details below). In cases where no euploid blastocysts were available, patients were counseled about the possibility of selecting blastocysts classified as mosaic for uterine transfer. All embryos described in this study were transferred in a prospective manner, meaning that prior knowledge of the mosaic status of the embryos was available in every case. In certain instances, more than one mosaic blastocyst was transferred at once, or one mosaic blastocyst was transferred along with a euploid blastocyst (generally of poorer quality), especially in patients with previous failed transfers.

Clinical outcomes were defined and collected as follows: Beta human Chorionic Gonadotropin (Beta-hCG) was measured by blood test on day 10 after transfer, with values > 5.0 mIU/mL considered positive and indicative of start of pregnancy. Presence of a gestational sac observed by endovaginal ultrasound at 3-5 weeks after transfer was considered evidence of implantation. Fetal heartbeat (FHB) was confirmed by endovaginal ultrasound 6-8 weeks after transfer. Non-Invasive Prenatal Testing (NIPT), amniocentesis, and birth information were voluntarily reported by the patient.

1
2
3
4 The experiments of serial biopsy concordance and cell proliferation and death made
5
6 use of supernumerary embryos donated to research by informed consent.
7
8

9 This study was approved by the Zouves Foundation IRB (OHRP IRB00011505).
10
11

12 13 14 **PGT-A**

15
16 NGS-based PGT-A was performed in-house using VeriSeq kit (Illumina) on a MiSeq
17
18 system (Illumina) following the manufacturer's protocol, in 24 sample runs. Karyotype
19
20 profiles were scored independently by two analysts using Bluefuse Multi Analysis
21
22 Software (Illumina), which depicts the copy number for each chromosome in a
23
24 sample. The platform is validated to detect segmental gains/losses of 20 Mb or larger
25
26 by the manufacturer, but can occasionally detect regions smaller than 2 Mb (11). A
27
28 molecular karyotype profile consistent with mosaicism was determined when a whole
29
30 chromosome or sub-chromosomal segment resulted in intermediate copy number
31
32 levels (in the range of 20-80% between whole numbers), following PGDIS guidelines
33
34 (http://www.pgdis.org/docs/newsletter_071816.html) and as previously described (6).
35
36
37
38
39
40
41
42

43 **Mosaic Study of Cell and DNA Mixes**

44
45 For cell analysis, the following cell lines were used: Coriell GM00425 (+8) and
46
47 GM04435 (+16, +21). Cells were cultured in RPMI 1640 (Thermo Fisher #12633-012)
48
49 containing 10% FBS (Seradigm 1500-050), GlutaMAX-I (Gibco 35050-061) and Pen-
50
51 Strep (Gibco 15140-122). Cells were detached with TrypLE (Gibco 12604021) and
52
53 re-suspended in culture medium. Single cells were collected and mixed in the
54
55 indicated ratios totaling 10 cells per sample and stored at -80°C until chromosomal
56
57
58
59
60
61
62
63
64
65

1
2
3
4 analysis by NGS as above. Each cell ratio was performed in triplicate, and one
5
6 representative karyotype profile is shown per tested ratio in the Fig. 1A.
7

8
9 For DNA analysis, we obtained genomic DNA extracted from two aneuploid fibroblast
10 cell lines. The first DNA sample (Coriell NA02948) was purified from cells trisomic for
11 chr13. The second DNA sample (Coriell NA00072) was purified from a cell line
12 advertised as containing a segmental loss in chr4p. We found additional
13
14 chromosomal errors (-13, mos(-5q,-11p,-12p,+17q)) in the sub-clonal line used in this
15 study (lot 1 with original extraction date 4/28/1997) and verified them in over 40 test
16 runs. In the singlicate mixing experiments, DNA was diluted down to represent
17 equivalent amounts contained in single diploid cells (6.6pg), such that a 50:50 mix of
18 DNAs contained 33pg of DNA from each cell line for a total of 66pg, equivalent to
19 DNA from 10 diploid cells per NGS reaction.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **Multiple Biopsy Experiment**

37
38 Mosaic blastocysts as determined from the original clinical TE biopsy were further
39 processed to isolate an ICM biopsy and a second TE biopsy as described elsewhere
40 (12). All biopsies underwent PGT-A as described above. DNA fingerprinting using a
41 previously described method (12) was performed on every biopsy to confirm it
42 originated from its intended blastocyst, thereby excluding the possibility of sample
43 mislabeling or contamination.
44
45
46
47
48
49
50
51
52
53
54

55 **Immunofluorescence**

56
57
58
59
60
61
62
63
64
65

1
2
3
4 Blastocysts were immersed in fixation buffer containing 4% paraformaldehyde (EMS
5 #15710) and 10% fetal bovine serum (FBS) (Seradigm 1500-050) in phosphate
6 buffered saline (PBS) (Corning MT21040CM) for 10 minutes (min) at room
7
8
9
10 temperature (rt), followed by three 1 min washes at rt in stain buffer composed of
11
12 0.1% Triton X-100 (TX-100) (Sigma X100-100ML) and 10% FBS in PBS. Samples
13
14 were then immersed in permeabilization buffer (0.5% TX-100, 10% FBS in PBS) for
15
16 30 min at rt, followed by three washes in stain buffer. Samples were then exposed to
17
18 stain buffer containing both primary antibodies (abs) each in 1:200 concentrations
19
20 over night at 4°C rocking on a nutator. Primary abs were rabbit anti-human phospho-
21
22 Histone H3 (Ser10) (pHH3) AlexaFluor555 conjugated monoclonal ab (Cell Signaling
23
24 #3475), rabbit anti-human Cleaved Caspase-3 (Asp175) AlexaFluor647 conjugated
25
26 monoclonal ab (Cell Signaling #9602), and mouse anti-human OCT-3/4 monoclonal
27
28 ab (Santa Cruz sc-5279). The next day, after three washes in stain buffer, samples
29
30 were immersed in stain buffer containing the secondary antibody goat anti-mouse
31
32 IgG AlexaFluor488 (Thermo Fisher A11029) at 1:500 concentrations for 2-3 hours at
33
34 rt. After three washes in stain buffer, samples were exposed to nuclear stain
35
36 (Hoechst 33342, Thermo Fisher H3570) diluted at 1:1000 in stain buffer for 30 min at
37
38 rt, followed by three more washes in stain buffer and subsequently imaged.
39
40
41
42
43
44
45
46
47
48
49

50 **Imaging and Computational Quantitation of Cell Proliferation and Death**

51
52 Stained blastocysts were placed in glass bottom dishes (MatTek P35G-1.5-20-C) in
53
54 small drops of stain buffer overlaid with mineral oil (Sigma M5904), and imaged with
55
56 a LSM 780 Confocal microscope (Zeiss). Image files in the .ism format were
57
58
59
60
61
62
63
64
65

1
2
3
4 uploaded into the software package Imaris 8.4.1 (Bitplane), and fluorescent channels
5
6 quantified for each blastocyst. The analysis was performed in a blinded fashion, as all
7
8 samples were quantified computationally with a uniform set of parameters,
9
10 independently of blastocyst classification. The parameters were:
11
12 Nuclear channel: spots with estimated diameter = 8.00um, background subtraction =
13
14 true, classify spots by quality above 13.6. OCT3/4 channel: spots with estimated
15
16 diameter = 6.00um, background subtraction = true, classify spots by quality above
17
18 11.0. pHH3 channel: spots with estimated diameter = 8.00um, background
19
20 subtraction = true, classify spots by quality above 15.5. Caspase-3 channel: surfaces
21
22 with enable smooth = true, surface grain size = 0.700um, enable eliminate
23
24 background = true, diameter of largest sphere = 8.00um, manual threshold value =
25
26 7.64, active threshold B = false, classify surfaces by number of voxels above 204.
27
28
29
30
31
32
33
34
35

36 **Statistics**

37
38 Analysis and graph preparation was done in Prism 6 (GraphPad). In Table 2, clinical
39
40 outcome comparisons between groups (defined in the table footnotes) were
41
42 performed with Fisher's exact test. Note that for the analyses in Table 2, for double
43
44 embryo transfer in which only one embryo was positive but its identity could not be
45
46 resolved due to matching sexes, each embryo received a value of 0.5. When this
47
48 scenario occurred in cases of triple embryo transfers, each embryo received a value
49
50 of 0.33. Final numbers are shown rounded to the closest integer.
51
52

53
54 In the mitosis/apoptosis quantitation experiment (Figure 1), differences between
55
56 groups were assessed by unpaired, two-tailed Student's t test with Welch's
57
58
59
60
61
62
63
64
65

1
2
3
4 correction. For all analyses: *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ns (not
5
6 significant), $P \geq 0.05$.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

RESULTS

Detection of chromosomal mosaicism with NGS-based PGT-A

Previous reports elegantly demonstrated that mixes of cell lines with different karyotypes resulted in mosaic profiles during PGT-A (3, 6, 13, 14), and that NGS showed superior resolution and more accurate mosaic calling than other platforms, including array comprehensive chromosome hybridization (aCGH) (13). We sought to use similar spike-in experiments to confirm the ability to detect chromosomal mosaicism in our hands, using an in-house PGT-A platform. As a first pass test, we observed that mixes of individual cells from lines with different aneuploidies yielded expected profiles consistent with mosaicism (Figure 1A). Then, in order to better establish the resolution of the technology in detecting mosaicism we performed experiments with DNA purified from cell lines. This allowed for more refined mixing ratios than with whole cells. We took advantage of cell line-derived DNA that displayed a very distinct karyotypic profile: copy number 2 for some parts of the genome (consistent with disomy), copy number 1 for other regions (consistent with monosomy), and intermediate levels (consistent with mosaicism) for yet other regions (Figure 2B, See DNA Cell Line B). This particular profile was replicated in over 40 sequencing runs, suggesting that at the time of DNA purification the cell line was not uniform and contained sub-clones resulting in mosaic profiles in some genomic regions. Mixing experiments with DNA from a different, uniformly aneuploid cell line showed superb resolution of mosaic profiles, with resolution of differences as small

1
2
3
4 as ~5% (Figure 2B). This was true for both whole chromosome and segmental (sub-
5
6 chromosomal) aneuploidies.
7

8
9 Together, these experiments confirmed the capability to detect instances of
10 chromosomal and segmental mosaicism with our in-house NGS-based PGT-A
11
12 pipeline.
13
14

15 16 17 18 19 **Clinical outcome of prospective mosaic embryo transfers tested by NGS-based** 20 21 **PGT-A**

22
23 Between October 2016 and June 2018, a total of 100 blastocysts classified as
24 mosaic by NGS-based PGT-A were transferred in a prospective manner (with
25 previous knowledge of their mosaic status) at a single IVF program as frozen embryo
26 transfers (Table 1). 50 were replaced into patients as single embryo transfers (SET),
27
28 26 as double embryo transfers (DET), and 6 as triple embryo transfers (TET). The
29 remaining 18 were transferred alongside one euploid embryo often of poor
30 morphological quality (Supplemental Table 1).
31
32
33
34
35
36
37
38
39

40
41 Compared to euploid blastocysts across all medical indications and ages
42 transferred in the same time period, the combined mosaic cohort had significantly
43 lower implantation rates per embryo (as determined by the presence of a gestational
44 sac)(49.6% vs 38.0%)(Table 2). Mosaic embryos also resulted in significantly lower
45 chances of developing a fetal heartbeat (FHB)(47.1% vs 30.0%)(Table 2). Patients
46 who had only a single euploid blastocyst available for transfer (without the possibility
47 of further embryo selection) experienced clinical outcomes that were inferior to the
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 combined group of euploid blastocysts, but were appreciably superior to the mosaic
5
6 blastocyst cohort (45.0% implantation, 42.2% FHB) (Table 2).
7
8

9 Of the 30 mosaic embryos resulting in FHB in this study, 11 were ongoing
10 pregnancies at the time of manuscript preparation and the remaining 19 have
11
12 resulted in births. One patient who had two mosaic embryos transferred
13
14 simultaneously went into labor at 23 weeks with spontaneous rupture of membranes
15
16 (SRM) leading to death of both newborns, which showed no other physiological
17
18 abnormalities upon examination.
19
20
21
22

23 In 7 cases where NIPT information could be retrieved from patients, all results
24 were normal. Amniocentesis was performed and data retrieved in 11 cases, 8 of
25
26 which tested normal. One case contained a balanced translocation, and two cases
27
28 showed microdeletions affecting segments smaller than the validated resolution of
29
30 the PGT-A platform used (Table 1).
31
32
33
34

35 Hence, the combined cohort of mosaic embryos showed overall decreased
36 implantation rates compared to euploids. Of the 30 cases showing a FHB there were
37
38 no instances of clinical miscarriage to date.
39
40
41
42
43
44

45 **Parameters of mosaicism affecting clinical outcome**

46
47

48 In our dataset, blastocysts showing mosaicism exclusively in a single segmental
49
50 (sub-chromosomal) region resulted in considerably better clinical outcomes than
51
52 blastocysts with other types of mosaicism (i.e. affecting multiple segments or any
53
54 number of whole chromosomes) (Table 2).
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 The degree of mosaicism, which is an estimate of the percentage of aneuploid
5 cells in the TE biopsy, did not correlate with clinical outcome in our dataset. We came
6
7 to the same conclusion when analyzing the data using two different cutoffs for 'low'
8
9 versus 'high' degree of mosaicism, and the differences between groups were
10
11 statistically insignificant (Table 2).
12
13
14

15
16 Interestingly, we observed a significant age effect on the success of mosaic
17
18 embryo transfers. When oocytes were retrieved from patients 34 years old or
19
20 younger, the clinical outcomes of their resulting mosaic blastocysts were
21
22 considerably better than those retrieved from patients greater than 34 years old
23
24 (Table 2). This was true for all types of mosaicism (Supplemental Table 2). In the
25
26 control group, euploid blastocysts fared equally well regardless of age.
27
28
29

30
31 Finally, we saw no difference in rates of implantation or FHB when the
32
33 mosaicism affected chromosomal gains (trisomies) versus losses (monosomies)
34
35 (Table 2).
36
37
38
39

40 **Mosaicism in the clinical TE biopsy is a poor predictor of chromosomal content** 41 42 **in the remaining blastocyst** 43

44
45 We hypothesized that some mosaic blastocysts might lead to normal pregnancies
46
47 because the clinical TE biopsy collected might not be representative of the entirety of
48
49 the blastocyst and particularly the ICM, which could be euploid. To test this
50
51 experimentally, we took an ICM biopsy and an additional TE biopsy from five
52
53 blastocysts that were originally classified as mosaic (Table 2). In three blastocysts,
54
55 the ICM biopsy was euploid, while in two blastocysts the ICM biopsy displayed
56
57
58
59
60
61
62
63
64
65

1
2
3
4 mosaicism that was reciprocal to that observed in the clinical TE biopsy. The
5
6 reciprocal patterns suggested incidences of chromosomal non-disjunction as the root
7
8 cause of mitotic error resulting in mosaicism (2). It has been suggested that a
9
10 reciprocal gain/loss in different biopsies of the same blastocyst is the strongest
11
12 evidence of true mosaicism (15). In regards to the second TE biopsies collected,
13
14 such reciprocal patterns were observed in three of the five blastocysts, while the two
15
16 other samples were euploid.
17
18
19
20

21 We performed the same multi-biopsy experiment on three blastocysts with
22
23 uniform aneuploidies as well as mosaic aneuploidies within their clinical TE biopsies
24
25 (Table 2). The uniform aneuploidies were always present in the subsequent biopsies
26
27 for all three embryos. The mosaic aneuploidies observed in the clinical TE biopsy
28
29 were replicated in subsequent biopsies in only one blastocyst (see Blastocyst 8,
30
31 Table 2). For that case, the degree of mosaicism varied greatly between biopsies
32
33 (30% in the clinical TE biopsy, versus 65% in the ICM and 50% in the second TE
34
35 biopsy).
36
37
38
39
40

41 We performed DNA fingerprinting on all sequenced biopsies to confirm there
42
43 were no sample mix-ups or contamination (Supplemental Figure 1). Notwithstanding
44
45 the limited sample size, this experiment demonstrated that embryos classified as
46
47 mosaic by PGT-A can be euploid in other regions of the blastocyst including the ICM,
48
49 and that the degree of mosaicism observed in the clinical TE biopsy are not strongly
50
51 correlated with the degree of mosaicism in subsequent biopsies.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 **Cell proliferation and death rates are elevated in mosaic blastocysts compared**
5
6 **to euploid blastocysts**
7

8
9 It has been suggested that euploid cells of mosaic embryos outcompete aneuploid
10 cells during development, possibly leading to chromosomally normal babies.
11

12
13
14 Experimental evidence for such a mechanism comes from a mouse model, in which
15
16 chimeras of euploid cells and aneuploid cells showed selective apoptosis of
17
18 aneuploid cells in the ICM and proliferative defects in aneuploid cells of the TE,
19
20 leading to a progressive depletion of aneuploid cells from the blastocyst stage
21
22 onwards (16).
23
24

25
26 If such a model were to apply in the context of human blastocysts generated
27
28 by IVF, we reasoned that mosaic embryos might display different patterns of cell
29
30 proliferation and death compared to euploid embryos. In order to test this hypothesis,
31
32 we performed immunofluorescence experiments on human embryos with markers of
33
34 mitosis (cell proliferation) and apoptosis (programmed cell death). Serine 10 on
35
36 histone H3 becomes phosphorylated specifically during mitotic chromatin
37
38 condensation, making phosphohistone 3 (pHH3) an oft-used marker of mitotic
39
40 activity. Caspase-3 is the central executioner of apoptosis, and its active (cleaved)
41
42 form is a validated marker of apoptotic cells. In addition, we stained all blastocysts in
43
44 this experiment with the nuclear dye Hoechst in order to visualize the nuclei of all
45
46 cells, as well as OCT-3/4 to be able to differentiate ICM cells from TE cells. After
47
48 staining euploid, mosaic, and aneuploid blastocysts, they were visualized by a
49
50 confocal microscope, and fluorescent signals were quantified computationally (Figure
51
52 2A and Supplemental Video 1).
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 In general, levels of mitosis were relatively low in euploid blastocysts (Figure
5
6
7 2B); even though no actively dividing ICM cells were detected in all five euploid
8
9 blastocysts used in our experiment, these findings do not suggest that cell
10
11 proliferation does not occur in the ICM of euploid blastocysts (which would be
12
13 impossible). Instead, it is important to note that immunofluorescent staining produces
14
15 a static snapshot of development, and rates or levels of cell proliferation and death
16
17 should be analyzed in a comparative fashion with other groups (i.e. mosaic and
18
19 aneuploid). Euploid blastocysts displayed negligible levels of apoptosis in the TE as
20
21 well as in the ICM (Figure 2B), agreeing with previous observations made in normal
22
23 human blastocysts (17, 18).
24
25
26
27

28
29 Interestingly, a large proportion of mosaic as well as aneuploid blastocysts
30
31 displayed medium or high levels of mitosis and apoptosis in the TE compared to
32
33 euploid blastocysts (Figure 2B). In the ICM, some mosaic and aneuploid blastocysts
34
35 displayed minimal/low levels of mitosis and apoptosis, and others displayed medium
36
37 or high levels of mitosis and apoptosis (Figure 2B). Together, this data suggest that
38
39 levels of cell proliferation and death are considerably higher in mosaic and aneuploid
40
41 blastocysts when compared to euploid blastocysts.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

DISCUSSION

PGT-A has undergone numerous technical advances since its inception. Compared to its initial form using FISH, which was limited to relatively few chromosomes, the most recent incarnation based on NGS permits the analysis of all chromosomes as well as detection of chromosomal mosaicism. What is more, mosaics can be further subdivided into categories by degree of mosaicism (low and high) and mosaic type (single or multiple segmental mosaics, whole chromosome mosaics, complex mosaics). This has undoubtedly added layers of complexity to the clinical interpretation of PGT-A results, and evidence-based guidelines are needed.

Preimplantation Genetic Diagnosis International Society (PGDIS) (19) and Controversies in Preconception, Preimplantation, and Prenatal Genetic Diagnosis (CoGEN) (20) provide position statements concerning prioritization of mosaic embryos for transfer, but the rationale behind them remains mainly theoretical. An alternative set of recommendations have been proposed, based on risk levels deduced from mosaic patterns observed in chorionic villus sampling (CVS) of the placenta and in products of conception (POC) (21). Nonetheless, a direct link between types of mosaicism at the blastocyst stage and clinical outcomes will only become defined over time with studies such as this one.

To date, all studies comparing euploid and mosaic embryo outcomes in IVF concur that embryos classified as mosaic can lead to babies that are healthy by routine examination, but with decreased success rates compared to euploids (3-7). Nonetheless, there is some disagreement between studies about which mosaic

1
2
3
4 parameters correlate with clinical outcome. For example, some have suggested that
5
6 a high degree of mosaicism (i.e. high proportion of aneuploid cells in the TE biopsy)
7
8 correlates with poorer outcomes. This relationship was described in a paper using a
9
10 mix of PGT-A technologies to detect mosaicism (7) as well as a study analyzing NGS
11
12 data in a retrospective manner, although in the latter report the trend was not
13
14 statistically significant (6). To our knowledge, this is the first prospective study relying
15
16 entirely on NGS, widely recognized as the most precise method to detect mosaicism
17
18 in PGT-A (8, 13, 22). Our data suggests that the degree of mosaicism should not be
19
20 used to prioritize mosaic embryos. This is contrary to current guidelines expressed by
21
22 PGDIS or CoGEN to prioritize selection of embryos for transfer, which in our opinion
23
24 should be amended.
25
26
27
28
29

30
31 This interesting point warrants discussion from a conceptual standpoint. Few
32
33 would dispute the notion that a mosaic blastocyst with a high percentage of
34
35 aneuploid cells is less likely to succeed than one with low percentage of aneuploid
36
37 cells, a concept first explored in an extensive manner by Verlinsky and colleagues
38
39 (23) and convincingly demonstrated experimentally in a mouse model of chimeric
40
41 blastocysts (16). It follows logically that if a clinical TE biopsy were a good
42
43 representative of the proportion of aneuploid cells in the remaining blastocyst,
44
45 embryos with high mosaicism in the TE biopsy should fare poorly. The salient point
46
47 shown in our data is that mosaicism in the TE biopsy is a poor representative of the
48
49 blastocyst. Mosaic blastocysts do not distribute aneuploid cells evenly, meaning there
50
51 is an inherent sampling error when collecting the TE biopsy. Therefore, we conclude
52
53 that the degree of mosaicism in the TE biopsy might be irrelevant to clinical outcome.
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 One parameter with a substantial effect on clinical outcome in our study was
5
6 type of mosaicism: single segmental mosaics fared better than all other types,
7
8 namely those affecting multiple segmental gains/losses, 1 or 2 whole chromosomes,
9
10 or complex mosaics. This observation agreed with a previous retrospective study (3),
11
12 although in our dataset the single segmental mosaic embryos did not fare quite as
13
14 well as euploid embryos. It has been suggested that the better clinical outcomes in
15
16 segmental mosaics might be due to the fact that segmental aneuploidies typically
17
18 result from DNA double strand break events, which often activate checkpoint
19
20 processes leading to cell cycle arrest or apoptosis (3). As a result, neighboring
21
22 euploid cells could quickly and efficiently dilute out cells containing segmental gains
23
24 or losses. Also, segmental aneuploidies resulting in acentric fragments do not contain
25
26 a centromere and cannot attach to the spindle during mitosis, potentially leading to
27
28 their loss during cell division (3). Therefore, our data supports the notion of prioritizing
29
30 single segmental mosaics for transfer above other mosaic types.
31
32
33
34
35
36
37

38 Another parameter to show a significant effect was age. Mosaic blastocysts
39
40 derived from oocytes retrieved from patients 34 years old or younger fared
41
42 significantly better than when derived from older patients. Interestingly, the 'young'
43
44 mosaic group yielded comparable results to euploid embryos, which in itself did not
45
46 display an age effect upon transfer. We can only speculate the biological reason for
47
48 this. Could any of the self-correcting mechanisms that have been proposed in mosaic
49
50 embryos (clonal depletion, preferential allocation, cell-endogenous rescue, see (24))
51
52 be more efficient in 'younger' blastocysts? It has been documented that, as opposed
53
54 to meiotic errors and uniform aneuploidy, rates of mitotic error and consequently
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 mosaicism at the blastocyst stage remain relatively constant with increasing age (2,
5
6 25). It is possible that 'younger' blastocysts manage to purge themselves of
7
8 mosaicism, while older blastocysts more often retain their aneuploid cell load and
9
10 accordingly become less likely to implant and reach birth. Another possibility is that
11
12 an increasing proportion of mosaic blastocysts generated from older patients
13
14 originated from trisomy rescue of uniformly aneuploid embryos, in turn possibly
15
16 leading to negative outcomes. These concepts warrant further investigation and to
17
18 our knowledge age has not been considered or analyzed as a mosaic parameter in
19
20 previous studies. If confirmed, in cases where a patient has multiple mosaic
21
22 blastocysts to choose from that were generated from different cycles at different
23
24 ages, we would recommend prioritizing the 'younger' ones.
25
26
27
28
29
30

31 We explored two concepts that might explain why embryos classified as
32
33 mosaic in PGT-A might lead to ongoing pregnancies and healthy births. The first, as
34
35 mentioned above, is that mosaicism in the TE biopsy is not a good predictor of
36
37 karyotype elsewhere in the blastocyst. We observed examples where the
38
39 corresponding ICM as well as a second TE biopsy were euploid. Other cases had
40
41 reciprocal mosaic aneuploidies in subsequent biopsies. In yet another scenario, a
42
43 blastocyst had the same mosaic aneuploidy in all three biopsies analyzed, but the
44
45 degree of mosaicism was different ('low' in the clinical TE biopsy, and 'high' in the
46
47 ICM and second TE biopsies. The inherent degree of sampling error in isolating a
48
49 biopsy from a mosaic blastocyst imposes a 'biological' source of false
50
51 positive/negative calls for mosaicism in PGT-A. Ultimately, this poor predictive power
52
53 of a mosaic TE biopsy vis-a-vis the remaining embryo might explain why embryos
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 classified as mosaic do occasionally implant and lead to healthy births but do so with
5
6 lower success rates than euploid embryos. Sometimes the mosaic TE biopsy will pair
7
8 with euploidy, other times with mosaicism, and yet other times with aneuploidy in the
9
10 remaining blastocyst. This is not to say that a mosaic TE biopsy will correspond in
11
12 equal rates to euploidy, mosaicism, and aneuploidy elsewhere. Only a larger and
13
14 detailed investigation analyzing serial biopsies in embryos classified as mosaic will
15
16 shed light into such ratios.
17
18
19
20

21 It must be acknowledged that there also exists an inherent risk for technical
22
23 error during PGT-A, which could produce profiles appearing mosaic when in fact the
24
25 biopsy in question is uniformly euploid or aneuploid. The mixing experiments suggest
26
27 that NGS-based PGT-A is excellent at identifying mosaicism when indeed present
28
29 (manifested as intermediate levels of karyotype profiles), but the inverse is not
30
31 necessarily true: an intermediate karyotype profile does not automatically mean that
32
33 a TE biopsy contains mosaicism. Artifacts introduced during WGA or NGS could
34
35 result in background noise that can produce such intermediate levels as well, falsely
36
37 resulting in karyotype profiles interpretable as mosaic. Our cell mixing experiments,
38
39 which were performed in biological triplicates, showed a false positive rate for
40
41 mosaicism of 0% but the sample size was small and there are aspects of TE biopsy
42
43 (resulting from laser use, biopsy isolation, handling etc.) that cannot be properly
44
45 modeled in cell mixes. Hence, it has been proposed that rather than categorically
46
47 diagnosing blastocysts as 'mosaic', PGT-A results should indicate a pattern
48
49 'consistent with possible mosaicism' (15).
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 The second concept we explored that could make mosaic blastocysts result in
5
6 healthy births is self-correction. It is known that the incidence of mosaicism
7
8 decreases through development (6), which could be explained by the out-competition
9
10 of aneuploid cells by euploid cells by differential cell proliferation and death. Indeed,
11
12 a chimeric mouse model for mosaicism has shown the progressive depletion of
13
14 aneuploid cells in the preimplantation embryo (16). In those experiments, aneuploid
15
16 cells in the fetal lineage (ICM) were largely eliminated by apoptosis, whereas those in
17
18 the placental lineage (TE) displayed severe proliferative defects. Our findings confirm
19
20 that in the human embryo, the dynamics of cell proliferation and death are different,
21
22 on average, between euploid, mosaic, and aneuploid blastocysts. This could
23
24 correspond to the proposed self-correction mechanism, as aneuploid cells might
25
26 proliferate slower or undergo apoptosis, and euploid cells compensate by elevating
27
28 their rates of proliferation. Unfortunately, existing tools and reagents do not allow us
29
30 to individually visualize the aneuploid and euploid cells in a mosaic human embryo,
31
32 which would be required to confirm this model. Yet, and notwithstanding the limited
33
34 sample size of our experiment, analysis on the blastocyst level showed statistically
35
36 significant differences between groups. Importantly, not all blastocysts classified as
37
38 mosaic had elevated rates of cell proliferation and death; some showed similar levels
39
40 to euploids. Presumably, those could be instances of blastocysts with mosaicism in
41
42 the TE biopsy, but euploidy elsewhere.

53 Centers using PGT-A have reported vastly different incidences of mosaic
54
55 embryos, anywhere from less than 4% up to 90% (15). Without context, such
56
57 comparisons are virtually meaningless. Equal thresholds, cutoffs, and technological
58
59
60
61
62
63
64
65

1
2
3
4 platforms need to be employed to make reasonable comparisons between groups.
5
6
7 Regardless of methods used to identify mosaics, the existence of chromosomally
8
9 mosaic embryos is an undisputed biological phenomenon. In our center, 18% of
10
11 blastocysts analyzed by PGT-A (n=3138) are classified as 'mosaic' using the
12
13 methods described in the manuscript. This is consistent with the 21% figure reported
14
15 by a large reference lab using the same standards as described here (22). While
16
17 biological and technical false positive/negative rates for mosaicism in PGT-A are
18
19 being established, a preponderance of evidence now shows that the 'mosaic'
20
21 category of blastocysts contains its own distinct set of clinical outcomes, different to
22
23 the uniform euploid or aneuploid categories. Considering the importance of the
24
25 mosaic group, evidence-based guidelines are vital to help prioritize them for transfer.
26
27
28
29

30
31 In summary, our findings suggest that after euploids, embryos displaying
32
33 single mosaic segmental gains and losses should be prioritized for transfer, along
34
35 with mosaic blastocysts derived from oocytes retrieved at younger patient age. On
36
37 the other hand, degree of mosaicism in the TE biopsy is not a relevant factor, and
38
39 blastocysts harboring mosaic monosomies and trisomies result in similar clinical
40
41 outcomes. Even though to our knowledge this is the largest single-center study of its
42
43 kind to date, we note that the sample size is still relatively limited and future larger
44
45 studies will need to corroborate or refute our findings. Finally, we provide
46
47 experimental data for two possibly parallel/additive mechanisms that may explain
48
49 why mosaic blastocysts can result in healthy babies, which has been a great concern
50
51 when transferring embryos classified as mosaic by PGT-A.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgements

We thank the entire team at Zouves Fertility Center for their invaluable contributions to this work, and all patients sharing clinical information or donating embryos to this study. The project was funded by the Zouves Foundation for Reproductive Medicine and Zouves Fertility Center.

TABLE LEGENDS**Table 1. List of mosaic blastocyst transfers**

¹ Estimated percentage of aneuploid cells in biopsy. When several chromosomes affected, highest value is indicated.

* Only applies to one embryo in the double FET, due to equal genders it cannot be deduced which one.

Only applies to one embryo in the triple FET, due to equal genders it cannot be deduced which one.

^a Single ventricle congenital heart defect detected at 22 weeks, NIPT was normal for all whole chromosomes and microdeletions tested, including DiGeorge deletion (22q11.2).

^b Microdeletion of one copy comprising 84.11 Kb at 2q13.

^c Balanced translocation of 1p and 16p.

^d Microdeletion of one copy less than 100 Kb (no further information available)

^e Spontaneous rupture of membranes (SRM) at 23 weeks leading to neonatal death of both babies, which showed no other physiological abnormalities upon examination

Table 2.**Analysis of mosaic parameters affecting clinical outcomes**

^a Compared to the 'Euploid All' group.

^b Compared to previous row (intra-group comparison)

^c Multi-biopsy analysis. Square brackets indicate the estimated degree of mosaicism observed in the karyotype profile.

Supplemental Table 1. List of double embryo transfers using one mosaic and one euploid blastocyst**Supplemental Table 2. Age of oocyte at retrieval affects clinical outcome in all types of mosaic embryo transfers**

FIGURE LEGENDS**Figure 1.****Validation of PGT-A method in accurate identification of mosaicism.**

- (A) Results from cell mixtures using a total of 10 cells per reaction.
- (B) Composite image from spike-in experiments with varying ratios of purified DNA from two aneuploid cell lines. Amounts of DNA mimic contents of single cells (6.6pg), resulting in 66pg per reaction. Results depict karyotype patterns consistent with the expected presence of mosaicism using NGS-based PGT-A. Note for example that the aneuploid region on chr5 is at ~50% loss when solely using DNA from cell line B, suggesting that each incremental mix with DNA from cell line A translates into a ~5% difference.

Figure 2.**Quantitation of cell proliferation and death in blastocysts.**

- (A) Left column shows representative immunofluorescent images of a hatching blastocyst classified as mosaic by PGT-A. Right column shows method of computational detection and quantitation. Note

1
2
3
4 that the image analysis software detects the concrete number
5
6 (count) of nuclei, ICM cells, and cells in mitosis. Apoptosis is
7
8 measured as arbitrary units (AU) of fluorescence in regions
9
10 displaying the signal in order to capture all apoptotic bodies,
11
12 including remaining vesicles of fractioned cells. Scale bar = 20 μ m
13
14
15
16
17

18
19 **(B)** Scatter dot plots depicting quantitation of mitosis and apoptosis in
20
21 TE and ICM. Each symbol represents one blastocyst. Lines indicate
22
23 mean with standard deviation. Sample size of each blastocyst group
24
25 is n=5 Euploids, n=11 Mosaics, n=14 Aneuploids. *, P < 0.05; **, P
26
27 < 0.01; ***, P < 0.001; ns (not significant), P \geq 0.05.
28
29
30
31
32

33 **Supplemental Figure 1.**

34 **Analysis of tissue relatedness in serial biopsies of blastocysts**

35
36 Graph depicting log-likelihood ratios of relatedness. In green, controls comparing
37
38 biopsies from embryos derived from unrelated patients, showing negative values. In
39
40 red, control comparison between biopsies from blastocysts derived from the same
41
42 patient (full-sibs) showing positive values. In purple, comparisons between paired
43
44 biopsies for each blastocyst analyzed in the study, showing positive log-likelihood
45
46 ratios of relatedness.
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

VIDEO LEGENDS

Supplemental Video 1. Video of confocal microscopy-imaged embryo after immunofluorescence staining, displaying quantitation method. This representative sample was classified as mosaic with PGT-A. Note that the image analysis software detects the concrete number (count) of nuclei (blue), ICM cells (green), and cells in mitosis (red). Apoptotic signal (white) is a measure of volume in regions displaying the signal in order to capture all apoptotic bodies, including remaining vesicles of fractioned cells.

BIBLIOGRAPHY

1. Kalousek DK, Dill FJ. Chromosomal mosaicism confined to the placenta in human conceptions. *Science* 1983;221:665-7.
2. Taylor TH, Gitlin SA, Patrick JL, Crain JL, Wilson JM, Griffin DK. The origin, mechanisms, incidence and clinical consequences of chromosomal mosaicism in humans. *Hum Reprod Update* 2014;20:571-81.
3. Fragouli E, Alfarawati S, Spath K, Babariya D, Tarozzi N, Borini A *et al.* Analysis of implantation and ongoing pregnancy rates following the transfer of mosaic diploid-aneuploid blastocysts. *Hum Genet* 2017;136:805-19.
4. Greco E, Minasi MG, Fiorentino F. Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid Blastocysts. *N Engl J Med* 2015;373:2089-90.
5. Lledo B, Morales R, Ortiz JA, Blanca H, Ten J, Llacer J *et al.* Implantation potential of mosaic embryos. *Syst Biol Reprod Med* 2017;63:206-8.
6. Munne S, Blazek J, Large M, Martinez-Ortiz PA, Nisson H, Liu E *et al.* Detailed investigation into the cytogenetic constitution and pregnancy outcome of replacing mosaic blastocysts detected with the use of high-resolution next-generation sequencing. *Fertil Steril* 2017;108:62-71 e8.
7. Spinella F, Fiorentino F, Biricik A, Bono S, Ruberti A, Cotroneo E *et al.* Extent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments. *Fertil Steril* 2018;109:77-83.
8. Kane SC, Willats E, Bezerra Maia EHMS, Hyett J, da Silva Costa F. Pre-Implantation Genetic Screening Techniques: Implications for Clinical Prenatal Diagnosis. *Fetal Diagn Ther* 2016;40:241-54.
9. Victor AR, Brake AJ, Tyndall JC, Griffin DK, Zouves CG, Barnes FL *et al.* Accurate quantitation of mitochondrial DNA reveals uniform levels in human blastocysts irrespective of ploidy, age, or implantation potential. *Fertil Steril* 2017;107:34-42 e3.
10. Gardner DK, Schoolcraft WB. In vitro culture of human blastocysts. . In: R. J, D. M, eds. *Towards reproductive certainty: fertility and genetics beyond*. Camforth, UK: Parthenon Publishing, 1999:378-88.

11. Zheng H, Jin H, Liu L, Liu J, Wang WH. Application of next-generation sequencing for 24-chromosome aneuploidy screening of human preimplantation embryos. *Mol Cytogenet* 2015;8:38.
12. Victor AR, Griffin DK, Brake AJ, Tyndall JC, Murphy AE, Lepkowsky LT *et al.* Assessment of aneuploidy concordance between clinical trophoctoderm biopsy and blastocyst. *Hum Reprod* In press.
13. Maxwell SM, Colls P, Hodes-Wertz B, McCulloh DH, McCaffrey C, Wells D *et al.* Why do euploid embryos miscarry? A case-control study comparing the rate of aneuploidy within presumed euploid embryos that resulted in miscarriage or live birth using next-generation sequencing. *Fertil Steril* 2016;106:1414-9 e5.
14. Tsuiko O, Zhigalina DI, Jatsenko T, Skryabin NA, Kanbekova OR, Artyukhova VG *et al.* Karyotype of the blastocoel fluid demonstrates low concordance with both trophoctoderm and inner cell mass. *Fertil Steril* 2018;109:1127-34 e1.
15. Capalbo A, Ubaldi FM, Rienzi L, Scott R, Treff N. Detecting mosaicism in trophoctoderm biopsies: current challenges and future possibilities. *Hum Reprod* 2017;32:492-8.
16. Bolton H, Graham SJ, Van der Aa N, Kumar P, Theunis K, Fernandez Gallardo E *et al.* Mouse model of chromosome mosaicism reveals lineage-specific depletion of aneuploid cells and normal developmental potential. *Nat Commun* 2016;7:11165.
17. Lalitkumar S, Boggavarapu NR, Menezes J, Dimitriadis E, Zhang JG, Nicola NA *et al.* Polyethylene glycated leukemia inhibitory factor antagonist inhibits human blastocyst implantation and triggers apoptosis by down-regulating embryonic AKT. *Fertil Steril* 2013;100:1160-9.
18. Ptak G, Zacchini F, Czernik M, Fidanza A, Palmieri C, Della Salda L *et al.* A short exposure to polychlorinated biphenyls deregulates cellular autophagy in mammalian blastocyst in vitro. *Hum Reprod* 2012;27:1034-42.
19. PGDIS. PGDIS position statement on chromosome mosaicism and preimplantation aneuploidy testing at the blastocyst stage. In: http://www.pgdis.org/docs/newsletter_071816.html, Accessed July 26, 2018, Online Statement.
20. CoGEN. CoGEN position statement on chromosomal mosaicism detected in preimplantation blastocyst biopsies In: https://ivf-worldwide.com/index.php?option=com_content&view=article&id=733&Itemid=464 Accessed July 26, 2018, Online Statement.
21. Grati FR, Gallazzi G, Branca L, Maggi F, Simoni G, Yaron Y. An evidence-based scoring system for prioritizing mosaic aneuploid embryos following preimplantation genetic screening. *Reprod Biomed Online* 2018;36:442-9.

1
2
3
4 22. Munne S, Wells D. Detection of mosaicism at blastocyst stage with the use of
5 high-resolution next-generation sequencing. *Fertil Steril* 2017;107:1085-91.
6

7
8 23. Evsikov S, Verlinsky Y. Mosaicism in the inner cell mass of human
9 blastocysts. *Hum Reprod* 1998;13:3151-5.
10

11 24. McCoy RC. Mosaicism in Preimplantation Human Embryos: When
12 Chromosomal Abnormalities Are the Norm. *Trends Genet* 2017;33:448-63.
13

14
15 25. McCoy RC, Demko ZP, Ryan A, Banjevic M, Hill M, Sigurjonsson S *et al.*
16 Evidence of Selection against Complex Mitotic-Origin Aneuploidy during
17 Preimplantation Development. *PLoS Genet* 2015;11:e1005601.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure1





FIG1

Figure2
[Click here to download high resolution image](#)




FIG2

TABLE 1

Embryo Number	Classification	Reported Summary	Beta-hCG +	Sec (Implantation)	Fetal Heart beat	Birth	Mosaic Level ¹	Embryo Evaluation	Oocyte Age	Age Embryo Recipient	Number of Previous FETs	Post Implantation Testing
Single Mosaic FETs												
1	Single Seg	mos(+9p)	Y	N	N	N	50%	5BB	30	30	0	
2	Single Seg	mos(-9p)	N	N	N	N	40%	5BB	37	37	3	
3	Single Seg	mos(-14q31.1q32.33)	N	Y	N	N	35%	6BB	37	37	1	
4	Single Seg	mos(-9q21.33q34.3)	Y	Y	Y	Y	50%	5BC	43	43	1	
5	Single Seg	mos(+5q12.3q35.3)	N	N	N	N	20%	5BC	40	40	0	
6	Single Seg	mos(+9q21.13q34.3)	Y	Y	Y	Y	30%	5BB	39	39	1	
7	Single Seg	mos(-4q22.2q35.2)	Y	N	N	N	20%	5BB	36	36	0	
8	Single Seg	mos(+3p24.1p21.1)	N	N	N	N	25%	5CC	41	41	1	
9	Single Seg	mos(+21p11.1q22.11)	Y	Y	Y	ongoing	30%	5BB	37	34	0	NIPT:Normal
10	Single Seg	mos(+19p)	N	Y	N	N	30%	5BB	42	42	1	
11	Single Seg	mos(+Xq22.3q28)	Y	Y	Y	ongoing ⁸	50%	5BB	42	42	0	NIPT:Normal
12	Single Seg	mos(-3q)	N	N	N	N	25%	5BC	39	42	0	
13	Single Seg	mos(+1p36.33q34.3)	Y	Y	Y	ongoing	70%	5BC	33	33	0	
14	Single Seg	mos(-7q)	Y	N	N	N	35%	5BB	39	39	2	
15	Single Seg	mos(-Xq21.1q28)	Y	Y	Y	ongoing	30%	5BB	40	33	0	
16	Single Seg	mos(-5q14.3q35.3)	N	N	N	N	20%	5BB	39	39	1	
17	Multiple Seg	mos(-2p25.3p24.1-21q22.1q22.3)	Y	Y	Y	Y	40%	5AB	33	33	2	Amnio:Normal
18	Multiple Seg	mos(+4q22.1q32.3-4q32.3q35.2)	N	N	N	N	60%	5BC	39	39	0	
19	Multiple Seg	mos(-1p36.11p32.3-5p13.3q14.3)	N	N	N	N	40%	6CC	40	40	0	
20	Multiple Seg	mos(-4p16.3q22.1+4q22.1q35.2)	N	N	N	N	50%	6CB	39	39	1	
21	Multiple Seg	mos(-2p25.3p23.1-8p)	N	N	N	N	30%	5BC	36	42	2	
22	Multiple Seg	mos(-1q-9q21.2q31.2)	N	N	N	N	50%	5BB	34	34	1	
23	Multiple Seg	mos(+4q32.3qter-10q22.2qter)	Y	Y	Y	ongoing	40%	5AB	24	36	6	NIPT:Normal
24	1 or 2 whole	mos(+14)	N	N	N	N	50%	5CC	31	31	1	
25	1 or 2 whole	mos(-15)	N	N	N	N	30%	5BB	36	36	0	
26	1 or 2 whole	mos(-20)	Y	N	N	N	20%	6BC	31	52	3	
27	1 or 2 whole	mos(+6)	N	N	N	N	20%	5BC	38	38	1	
28	1 or 2 whole	mos(+3)	Y	Y	Y	Y	60%	5BC	33	26	3	NIPT:Normal; Amnio:Normal
29	1 or 2 whole	mos(-13)	N	N	N	N	50%	4BB	37	37	0	
30	1 or 2 whole	mos(+3)	N	N	N	N	25%	4CC	39	39	1	
31	1 or 2 whole	mos(-3)	N	N	N	N	35%	4BB	34	34	0	
32	1 or 2 whole	mos(+17)	N	N	N	N	25%	5BC	42	42	0	
33	1 or 2 whole	mos(-X)	Y	N	N	N	25%	5BB	33	33	3	
34	1 or 2 whole	mos(-11)	Y	Y	N	N	40%	5BB	38	38	3	
35	1 or 2 whole	mos(+9)	N	N	N	N	40%	4BC	44	44	0	
36	1 or 2 whole	mos(-8)	N	N	N	N	50%	5BC	37	37	0	
37	1 or 2 whole	mos(+14)	N	N	N	N	20%	5BB	43	43	1	
38	1 or 2 whole	mos(-18)	Y	N	Y	ongoing	20%	6BA	43	25	0	NIPT:Normal
39	1 or 2 whole	mos(-7+22)	N	N	N	N	45%	6AA	35	35	3	
40	1 or 2 whole	mos(+2-15)	Y	N	N	N	25%	5BC	43	43	0	
41	1 or 2 whole	mos(-2-8)	Y	Y	Y	ongoing	30%	5BB	34	34	2	Amnio: microdeletion ⁹
42	1 or 2 whole	mos(+1-20)	Y	Y	Y	ongoing	60%	5BB	39	39	2	NIPT:Normal
43	1 or 2 whole	mos(+22)	Y	N	N	N	30%	5BB	41	41	2	
44	Complex	mos(+1,+20,-22)	Y	Y	N	N	30%	5BB	34	34	1	
45	Complex	mos(-9,-11,-18,+19)	Y	Y	Y	Y	40%	6BC	34	34	0	NIPT:Normal
46	Complex	mos(-3,-4,+16)	Y	N	N	N	30%	5BC	35	35	0	
47	Complex	mos(-3,-6,-8,-15,-18)	N	N	N	N	40%	5BC	38	38	1	
48	Complex	mos(+3,+5p15q14.3+19)	Y	Y	Y	Y	35%	5BC	42	42	0	
49	Complex	mos(-1p,+13,+14,+15,+20,+22)	Y	Y	N	N	50%	5BC	41	41	0	
50	Complex	mos(+1,-7,-16,+17,+21q22.12q22.3,+22)	Y	Y	Y	ongoing	30%	3BB	26	45	0	
Double FET (1 Mosaic transferred together with 1 Euploid Embryo)												
51	Single Seg	mos(+11p)	Y	N	N	N	30%	5CC	41	41	0	
52	Single Seg	mos(+12q14.1q24.31)	Y	Y	Y	Y	30%	5BC	37	37	0	
53	Single Seg	mos(-5q)	N	N	N	N	45%	5BB	34	34	1	
54	Single Seg	mos(-1p36.33p31.1)	Y	Y	Y	Y	25%	5AB	34	34	2	Amnio:Normal
55	Single Seg	mos(+1p36.31q32.2)	N	N	N	N	40%	5BB	35	35	1	
56	Single Seg	mos(-10q23.1q26.3)	N	N	N	N	30%	5BB	41	41	1	
57	Single Seg	mos(+8q22.31qter)	(Y)	N	N	N	40%	5BC	37	37	1	
58	Single Seg	mos(-3q)	(Y)	(Y)	(Y)	(ongoing)	25%	3BB	42	42	1	
59	Multiple Seg	mos(-1q21.3qter-21p11.1q21.2)	N	N	N	N	30%	6BB	31	31	1	
60	1 or 2 whole	mos(-17)	Y	N	Y	Y	30%	6BB	39	39	1	Amnio: translocation ⁹
61	1 or 2 whole	mos(-14)	N	N	N	N	20%	5BC	29	29	0	
62	1 or 2 whole	mos(+17)	N	N	N	N	25%	5CC	39	39	1	
63	1 or 2 whole	mos(-16)	Y	Y	Y	ongoing	40%	5BB	24	46	0	
64	1 or 2 whole	mos(-21)	(Y)	N	N	N	25%	5BB	38	38	3	
65	1 or 2 whole	mos(+15q14.22.31+21)	N	N	N	N	35%	5CC	35	35	2	
66	1 or 2 whole	mos(-17p13.2q25.3+1p31.3p21.3)	N	N	N	N	45%	6CB	40	40	2	
67	1 or 2 whole	mos(-10,+5)	Y	Y	Y	Y	20%	5BB	33	33	1	Amnio:Normal
68	Complex	mos(-14,-18q,+18p)	N	N	N	N	65%	4CC	40	40	0	
Double FET (2 Mosaic)												
69	Complex	mos(-1,+13,-20)	Y	Y	Y	Y	20%	5BC	34	34	1	Amnio:Normal
70	1 or 2 whole	mos(-2)	N	N	N	N	25%	5CC	34	34	1	
71	Multiple Seg	mos(-3p,+21p11.1q21.2)	(Y)*	(Y)*	N	N	40%	5BC	26	32	2	
72	1 or 2 whole	mos(-11)	(Y)*	(Y)*	N	N	25%	5BC	26	26	2	
73	1 or 2 whole	mos(+3p14.3p12.1,+7)	(Y)*	(Y)*	(Y)*	(Y)*	35%	5BB	33	33	1	(Amnio:Normal)*
74	1 or 2 whole	mos(+22)	(Y)*	(Y)*	(Y)*	(Y)*	30%	5BB	33	33	1	(Amnio:Normal)*
75	Single Seg	mos(+16p)	Y	Y	Y	Y	30%	5BB	32	32	1	Amnio: microdeletion ⁹
76	1 or 2 whole	mos(-19)	Y	Y	Y	Y	30%	5BC	32	32	1	
77	Multiple Seg	mos(+1p,-1q)	Y	Y	Y	Y*	30%	5AB	34	35	2	
78	Single Seg	mos(+11p11.2q14.1)	Y	Y	Y	Y*	30%	6BA	34	35	2	
79	Complex	mos(+12,+14,+16,+18,+19,-X)	(Y)*	(Y)*	(Y)*	(Y)*	50%	3BC	36	36	5	(Amnio:Normal)*
80	1 or 2 whole	mos(+16)	(Y)*	(Y)*	(Y)*	(Y)*	40%	5CB	36	36	5	(Amnio:Normal)*
81	Single Seg	mos(-2q35q37.3)	(Y)*	(Y)*	N	N	50%	5BC	36	42	1	
82	1 or 2 whole	mos(-4)	(Y)*	(Y)*	N	N	25%	5BB	36	42	1	
83	Complex	mos(+3,+6,-14,-15,+20)	N	N	N	N	60%	5CC	27	39	0	
84	Complex	mos(+8,+12,-21)	N	N	N	N	50%	4BC	27	39	0	
85	Single Seg	mos(+10q21.3q26.3)	Y	Y	Y	Y	45%	5BB	36	36	1	Amnio:Normal
86	Single Seg	mos(-1p36.33p32.3)	Y	Y	Y	Y	60%	5BB	36	36	1	Amnio:Normal
87	Single Seg	mos(-2p25.3p24.3)	(Y)*	(Y)*	N	N	25%	4BB	34	34	0	
88	1 or 2 whole	mos(+2)	(Y)*	(Y)*	N	N	25%	5CB	34	34	0	
89	Complex	mos(+11p11.2q12.2,+20,+22)	(Y)*	N	N	N	25%	5CC	38	28	7	
90	1 or 2 whole	mos(+19)	(Y)*	N	N	N	30%	5BB	38	28	7	
91	Single Seg	mos(-5p)	N	N	N	N	40%	3CC	39	39	0	
92	Single Seg	mos(+14q32.12q32.33)	N	N	N	N	35%	5CB	39	39	0	
93	Multiple Seg	mos(+3p14.2p14.1+16p13.3p12.1,+18q11.2q24.3)	(Y)*	(Y)*	(Y)*	(ongoing)*	50%	5CC	42	42	1	
94	1 or 2 whole	mos(-3,-X)	(Y)*	(Y)*	(Y)*	(ongoing)*	20%	5BC	42	42	1	
Triple FET (3 Mosaic)												
95	Single Seg	mos(+13q13.3q33.3)	(Y)*	N	N	N	20%	5CC	40	40	1	
96	1 or 2 whole	mos(+5,+20)	(Y)*	N	N	N	40%	5CC	40	40	1	
97	1 or 2 whole	mos(+19)	(Y)*	N	N	N	50%	5BC	40	40	1	
98	1 or 2 whole	mos(-7,-17)	(Y)*	(Y)*	N	N	50%	5BB	40	40	3	
99	1 or 2 whole	mos(-4)	(Y)*	(Y)*	N	N	30%	5BB	40	40	3	
100	1 or 2 whole	mos(+21)	(Y)*	(Y)*	N	N	40%	5BB	40	40	3	

TABLE 2

Type	Embryos Transferred	Beta-hCG +	Sac [Implantation]	Fetal Heartbeat	Beta-hCG + (%)	Sac (%) [Implantation]	Fetal Heartbeat (%)	P Value Sac [Implantation]	P Value Fetal Heartbeat	Average Age	Average Mosaicism
Euploid All	478	296	237	225	61.9%	49.6%	47.1%			37.4	N/A
Euploid No Selection	109	68	49	46	62.4%	45.0%	42.2%	0.3974 (ns) ^a	0.3949 (ns) ^a	36.9	N/A
Mosaic All	100	49	37	30	49.0%	38.0%	30.0%	0.0273 (*) ^a	0.0019 (**) ^a	36.4	36%

Mos. Single Segmental	33	19	15	13	57.6%	45.5%	39.4%	0.7203 (ns) ^a	0.4717 (ns) ^a	37.6	35%
Mos. Multiple Segmental	11	4	4	3	36.4%	36.4%	27.3%	0.5446 (ns) ^a	0.2331 (ns) ^a	34.4	42%
Mos. 1 or 2 Whole Chr.	43	18	12	10	41.9%	27.9%	23.3%	0.0067 (**) ^a	0.0035 (**) ^a	36.6	33%
Mos. Complex (>2 Chr)	13	8	6	4	61.5%	46.2%	30.8%	1.0000 (ns) ^a	0.2748 (ns) ^a	34.7	40%

Level Range of Mosaicism	Embryos Transferred	Beta-hCG +	Sac [Implantation]	Fetal Heartbeat	Beta-hCG + (%)	Sac (%) [Implantation]	Fetal Heartbeat (%)	P Value Sac [Implantation]	P Value Fetal Heartbeat	Average Age	Average Mosaicism
20% – 50%	78	39	28	23	50.0%	35.9%	29.5%			36.4	-
50% – 80%	22	10	9	7	45.5%	40.9%	31.8%	0.8031 (ns) ^b	0.7992 (ns) ^b	36.5	-
20% – 40%	58	32	21	16	55.2%	36.2%	27.5%			36.7	-
40% – 80%	42	17	16	14	40.5%	38.1%	33.3%	1.0000 (ns) ^b	0.6590 (ns) ^b	36.0	-

Age of Oocyte (years)	Embryos Transferred	Beta-hCG +	Sac [Implantation]	Fetal Heartbeat	Beta-hCG + (%)	Sac (%) [Implantation]	Fetal Heartbeat (%)	P Value Sac [Implantation]	P Value Fetal Heartbeat	Average Age	Average Mosaicism
≤34 Euploid	141	95	72	69	67.4%	51.1%	48.9%			-	N/A
>34 Euploid	337	201	165	156	59.6%	49.0%	46.2%	0.6893 (ns) ^b	0.6164 (ns) ^b	-	N/A
≤34 Mosaic All	34	21	19	16	61.8%	55.9%	47.1%			-	35%
>34 Mosaic All	66	28	18	14	42.4%	27.3%	21.2%	0.0082 (**) ^b	0.0111 (*) ^b	-	36%

Mosaic Abnormality	Embryos Transferred	Beta-hCG +	Sac [Implantation]	Fetal Heartbeat	Beta-hCG + (%)	Sac (%) [Implantation]	Fetal Heartbeat (%)	P Value Sac [Implantation]	P Value Fetal Heartbeat	Average Age	Average Mosaicism
Gain	38	18	13	12	47.4%	34.2%	31.6%			37.8	35%
Loss	42	20	16	11	47.6%	38.1%	26.2%	0.8172 (ns) ^b	0.6296 (ns) ^b	36.2	33%

^cBlastocysts with PGT-A Classification: Mosaic Only

	Blastocyst 1	Blastocyst 2	Blastocyst 3	Blastocyst 4	Blastocyst 5
Clinical TE Biopsy	XY, mos(-10 [50%])	XY, mos(+15 [50%])	XX, mos(-3 [65%])	XY, mos(+3 [65%], +9 [40%], +11 [45%])	XX, mos(-12 [40%], +18 [45%], +21[50%])
ICM Biopsy	XY, euploid	XY, mos(-15 [50%])	XX, mos(+3 [40%])	XY, euploid	XX, euploid
Second TE Biopsy	XY, mos(+10 [25%])	XY, mos(-15 [50%])	XX, mos(+3 [75%])	XY, euploid	XX, euploid

^cBlastocysts with PGT-A Classification: Uniform Aneuploid and Mosaic

	Blastocyst 6	Blastocyst 7	Blastocyst 8
Clinical TE Biopsy	XX,+22, mos(+1q21.2-q44 [70%])	XX, -22, mos(-10 [80%])	XX,+14, -21, mos(-16q [30%])
ICM Biopsy	XX, +22	XX, -22, mos(+1 [30%], -X [25%])	XX,+14, -21, mos(-16q [65%])
Second TE Biopsy	n/a	XX, -22, mos(+19 [35%])	XX,+14, -21, mos(-16q [50%])

Table Suppl. 1

Transfer #	Mosaic Embryo Grade	Euploid Embryo Grade	Beta-hCG	Mosaic Sac	Euploid Sac	Mosaic Heartbeat	Euploid Heartbeat
1	5BC	5AB	+	Y	Y	Y	Y
2	5AB	5BB	+	Y	Y	Y	Y
3	5BB	5BB	+	Y	Y	Y	Y
4	6BB	4CC	+	Y	N	Y	N
5	5BB	5CC	+	Y	N	Y	N
6	5CC	5CB	+	N	N	N	N
7	3BB	6CB	+	(Y)	(Y)	(Y)	(Y)
8	5BC	5BC	+	N	N	N	N
9	5BB	5BB	+	(Y)	(Y)	N	N
10	5CC	5CC	-	N	N	N	N
11	6CB	5BB	-	N	N	N	N
12	5BB	5CC	-	N	N	N	N
13	5BB	5CC	-	N	N	N	N
14	4CC	5CC	-	N	N	N	N
15	5CC	5BB	-	N	N	N	N
16	5BB	5BB	-	N	N	N	N
17	5BC	4CC	-	N	N	N	N
18	5BB	5BC	-	N	N	N	N

Table Suppl. 2

Age of Oocyte (years)	Embryos Transferred	Beta-hCG +	Sac [Implantation]	Fetal Heartbeat	Beta-hCG + (%)	Sac (%) [Implantation]	Fetal Heartbeat (%)	P Value Sac [Implantation]	P Value Fetal Heartbeat	Average Mosaicism
≤34 Euploid	141	95	72	69	67.4%	51.1%	48.9%			N/A
>34 Euploid	337	201	165	156	59.6%	49.0%	46.2%	0.6893 (ns) ^b	0.6164 (ns) ^b	N/A
≤34 Mosaic All	34	21	19	16	61.8%	55.9%	47.1%			35%
>34 Mosaic All	66	28	18	14	42.4%	27.3%	21.2%	0.0082 (**) ^b	0.0111 (*) ^b	36%

≤34 Mos. Single Segm.	7	6	5	4	85.7%	71.4%	57.1%			39%
>34 Mos. Single Segm.	26	13	10	9	50.0%	38.5%	34.6%	0.2028 (ns) ^b	0.3926 (ns) ^b	34%
≤34 Mos. Multi Segm.	6	3	3	3	50.0%	50.0%	50.0%			38%
>34 Mos. Multi Segm.	5	1	1	1	20.0%	20.0%	20.0%	0.5455 (ns) ^b	0.5455 (ns) ^b	46%
≤34 Mos. 1 or 2 Whole Chr.	15	9	7	6	60.0%	46.7%	40.0%			31%
>34 Mos. 1 or 2 Whole Chr.	28	9	5	4	32.1%	17.9%	13.0%	0.0739 (ns) ^b	0.0726 (ns) ^b	34%
≤34 Mos. Complex	6	4	4	3	66.7%	66.7%	50.0%			38%
>34 Mos. Complex	7	4	2	1	57.1%	28.5%	14.3%	0.2861 (ns) ^b	0.2657 (ns) ^b	42%

